Updates on regulatory reform and plans to support innovation.
Similar Posts
Abrysvo▼ (Pfizer RSV vaccine) and Arexvy▼ (GSK RSV vaccine): be alert to a small risk of Guillain-Barré syndrome following vaccination in older adults
There is a small increase in the risk of Guillain-Barré syndrome following vaccination with Abrysvo (Pfizer respiratory syncytial virus (RSV) vaccine) and Arexvy (GSK RSV vaccine) in adults aged 60 years and older. Healthcare professionals should advise all recipients of Abrysvo and Arexvy that they should be alert to signs and symptoms of Guillain-Barré syndrome and, if they occur, to seek immediate medical attention as it requires urgent treatment in hospital.
MHRA scientists contribute to international study on novel oral polio vaccine stability
Study confirms vaccine being used in global efforts to achieve and sustain polio eradication is successfully interrupting polio outbreaks whilst minimising risk of new vaccine-derived outbreaks in Uganda
Manufacturer’s Online Reporting Environment (MORE)
A digital platform designed to facilitate the reporting, monitoring, and management of medical device incidents.
UK approves the first twice yearly biological medicine for asthma and severe chronic rhinosinusitis with nasal polyps
As with any medicine, the MHRA will keep the safety and effectiveness of depemokimab under close review.
MHRA Safety Roundup: February 2026
Summary of the latest safety advice for medicines and medical device users
Clinical trials: Non-investigational medicinal products
Guidance on using non-investigational medicinal products in a clinical trial.